FIND A CLINICAL TRIAL
In conjunction with our mission to advance the science and practice of clinical psychopharmacology through education and research, ASCP is committed to the support and promotion of clinical trials. We encourage practitioners and patients to investigate and participate in clinical trials when available and appropriate. To list a clinical trial on the website, please fill out the form below or submit information to info@ascpp.org.
Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults (D1AMOND)
New York University (NYU) Langone Child Study Center, NY is currently recruiting for the following study. This is a Phase 3, multicenter trial evaluating the efficacy, safety and tolerability of ecopipam tablets in children, adults, and adolescents in the treatment of Tourette’s Disorder. We are recruiting participants aged 6 years or more, weighing over ~40 pounds, with a diagnosis of Tourette’s Disorder, with a YGTSS score of >20. Patients will be enrolled in an open-label period followed by a double-blind, placebo-controlled, randomized withdrawal period.
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults with Major Depressive Disorder (MDD) (uAspire)
The purpose of this clinical research study is to determine the safety and effectiveness of a treatment with psilocybin in adults diagnosed with major depressive disorder (MDD). Currently available treatments for depression may not work for everyone, so alternative treatments are being sought through clinical research studies. The uAspire study is testing a single oral dose of an investigational drug (psilocybin) for the treatment of MDD. We will look at the investigational drug to learn how well it relieves the symptoms of a major depressive episode compared to treatment versus a placebo group. Participants will also receive psychosocial support—sessions that address a person's emotional, social, mental and spiritual needs—throughout the study from trained study facilitators.
NCT05303064, OLZ/SAM vs Olanzapine to Evaluate Weight Gain in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
This is a Phase 3, randomized, double-blind, 52-Week study of OLZ/SAM vs Olanzapine to evaluate weight gain as assessed by change in BMI Z-Score in pediatric subjects with schizophrenia or bipolar I disorder (ENLIGHTEN-Youth). This study is sponsored by Alkermes Inc. and is lead by investigator Adelaide Robb, M.D.
Enter a Research Registry Survey
The UCLA Mental Health and Health Technology Research Registry allows members of the public to voluntarily register themselves to be contacted for future research study participation relating to mental health or smart health technology. You can play a vital role in the progress of mental health research. By joining the registry, you could help advance research using technology, such as smartwatches, tablets, virtual reality, chatbots, remote consultations, electronic surveys and sleep quality monitors. Many studies allow the participants to keep the devices used during the research and compensation is often available.